Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
about
Successful adoptive transfer and in vivo expansion of haploidentical γδ T cellsRecent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescentsTargeted Therapies in Adult B-Cell MalignanciesWhat lessons can be learned from γδ T cell-based cancer immunotherapy trials?γδ T Cell Immunotherapy-A ReviewRole of natural killer and Gamma-delta T cells in West Nile virus infectionγδ T cells for cancer immunotherapy: A systematic review of clinical trialsHarnessing the power of Vδ2 cells in cancer immunotherapyThe role of gamma delta T cells in haematopoietic stem cell transplantationHaploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular TherapySelf/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancerA Subset of Protective γ9δ2 T Cells Is Activated by Novel Mycobacterial Glycolipid ComponentsA rapid crosstalk of human gammadelta T cells and monocytes drives the acute inflammation in bacterial infectionsHighly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.Human cytomegalovirus elicits fetal gammadelta T cell responses in uteroAdoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.{gamma}{delta} T cell homeostasis is established in competition with {alpha}{beta} T cells and NK cells.Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens.Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates.Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection.Activating and propagating polyclonal gamma delta T cells with broad specificity for malignanciesImmune therapy for breast cancer in 2010-hype or hope?Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity.Targeting γδ T cells for immunotherapy of HIV diseasePreferential Th1 cytokine profile of phosphoantigen-stimulated human Vγ9Vδ2 T cells.γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.Plasticity of γδ T Cells: Impact on the Anti-Tumor ResponseClinical applications of gamma delta T cells with multivalent immunity.Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.The Vγ9Vδ2 T Cell Antigen Receptor and Butyrophilin-3 A1: Models of Interaction, the Possibility of Co-Evolution, and the Case of Dendritic Epidermal T Cells.A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.Vgamma2Vdelta2 T Cell Receptor recognition of prenyl pyrophosphates is dependent on all CDRsRapamycin increases the yield and effector function of human γδ T cells stimulated in vitro.Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoireClinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.
P2860
Q21245481-EFF575C4-51E7-443D-BA38-FD2BB590B215Q26750995-2606F53C-14A1-467F-BEC0-D7BB5263B069Q26783195-97E9CCBC-467B-47F1-BB61-ED029AF4793EQ26849323-009C2FF6-0BB8-4896-87E8-FB880329C78AQ26995102-A81828E6-4C73-49DF-BC04-7C6F10115312Q27007830-1CDDFF02-7F6C-4B57-B652-68753CEB75F1Q27021705-112B9FDC-9B6C-4EBF-8275-DA2DA6CC533DQ27027547-A77213AA-3645-4413-AFDD-DB2B1BD23575Q27030355-6ED81EBC-4063-4D7A-A217-C13F0EBC73F7Q28085397-4089C149-DA8F-4C9A-A118-8F44B7DB475AQ28287583-4C9D4770-CB01-4EDE-A757-9AFFD4BB5460Q28659468-45AEDAC1-80E2-46A4-B1C3-03A142EC58B1Q28829233-D9F7454C-A04C-4BF9-9961-4C1974BA3AE0Q33410795-FEBB7539-D2EE-4EEE-83B7-91F94CBC36BAQ33455830-3981D65B-7819-4382-A88A-777707E0F999Q33795023-10AFBB4B-8FA3-4DAD-AA7B-61BA07E515E1Q33905819-54CE663C-64B8-4F5C-91F7-812203481A18Q33920919-963AEA9B-39F9-4695-ADED-836612E74947Q34055649-33A1FEEA-D144-491B-B891-C3D641EAF0F0Q34077388-73F1DE80-8AC6-41FD-81A4-6FD919A40874Q34170227-D5D39F91-613F-46EA-AF2E-5DA04301EAEAQ34230320-8928A69B-E3DF-40D0-8AD6-4A0A5BDDBCE6Q34372167-0D345914-9C1B-4B17-AECA-ABB3277CCFA1Q34395222-AD90445C-66CE-46C2-92E3-5642A6A1C58FQ34496948-3618D962-A34D-495C-9D6E-FF7C7798C1AFQ34517192-67C1F500-AC6B-4267-B065-1CAAE1A98F4FQ34541467-8B3B79E4-F176-43CE-8585-E416098BF002Q34560345-CC86F3CB-929F-4C4B-B982-7992A31A7DD8Q34585223-6DF5DF01-A23C-44D6-BC4B-640455DC865BQ34595188-E568EA21-5572-4970-9FC2-F2F8D388D907Q34612619-A99AA182-3E64-44C5-A9F2-AE5370D81636Q34652408-FC7E48B4-0864-480E-9DA2-F6325BDE41CFQ34677859-1334D612-996B-4428-A1DC-06168C39F738Q34681370-D21BBD4C-E426-471F-A921-1A5AFBDB3F84Q34741552-0A6BF6A1-655A-44E0-ACB6-DF330FBF01A3Q34743969-72AE8353-9651-4A4C-B561-0827B3AEABAAQ34749889-D34B4951-3DCD-498E-AED8-AD8476FE214FQ34802235-0FA023B9-2F7D-49AE-8F58-B0E53E52B16EQ35090079-C918E012-6637-4787-82E3-91765206F8BAQ35208161-AF3B42AE-D2D9-43AA-B337-4C6CB874D701
P2860
Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
@en
Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
@nl
type
label
Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
@en
Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
@nl
prefLabel
Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
@en
Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
@nl
P2093
P1433
P1476
Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
@en
P2093
Florian Weissinger
Martin Wilhelm
Peter Reimer
Susanne Eckstein
Thomas Ruediger
Volker Kunzmann
P304
P356
10.1182/BLOOD-2002-12-3665
P407
P577
2003-03-06T00:00:00Z